VIM and neoplasm: We have shown that immunofluorescent antibody co-staining for EpCAM, Vimentin and CD24 can separate disseminating EMT CSCs from the stromal content of human tumours, a challenge which has confounded previous attempts to develop a predictive EMT signature (Tan et al., 2014).